von Ruecker A A, Wild M, Rao G S, Bidlingmaier F
Institut für Klinische Biochemie, Universität Bonn, F.R.G.
J Clin Chem Clin Biochem. 1989 Sep;27(9):531-7. doi: 10.1515/cclm.1989.27.9.531.
Elevated concentrations of atrial natriuretic peptide reportedly mitigate acute renal failure in vivo and in the isolated perfused kidney (M. Nakamoto, J.I. Shapiro, P.F. Shanley, L. Chan & R.W. Shrier (1987) J. Clin. Invest. 80, 698-705; S.G. Shaw, J. Weidmann, J. Hodler, A. Zimmermann & A. Paternostro (1987) J. Clin. Invest. 80, 1232-1237). Since atrial natriuretic peptide has been shown to be a potent vasodilator, this beneficial effect may be due entirely to improved haemodynamics. To determine whether atrial natriuretic peptide also has a protective effect at the cellular level, rat hepatocyte cell cultures were treated with atrial natriuretic peptide prior to or after induction of cell damage by hypoxia (0.5% O2 for 4 h) or reactive oxygen (hypochlorous acid). Bleb formation, degradation of radiolabeled trichloroacetic acid-precipitable peptides, release of lactate dehydrogenase and trypan blue exclusion were used as indicators of cell damage. Atrial natriuretic peptide treatment distinctly protected the cell cultures against damage in both cases. This beneficial effect of atrial natriuretic peptide was partly mimicked by sodium nitroprusside, which, like atrial natriuretic peptide, largely increased the cellular cGMP content. 6-Anilino-5,8-quinolinedione (Ly 83583), an inhibitor of particulate guanylate cyclase, blocked the protective effect of atrial natriuretic peptide. Therefore a cGMP-mediated mechanism seems to be involved in the cytoprotective action of atrial natriuretic peptide. Fluorometric measurements using the Ca2+-sensitive dye Quin-2 showed that the elevation of intracellular Ca2+ after cellular insult by hypochlorous acid is prevented by atrial natriuretic peptide. These results suggest that atrial natriuretic peptide may attenuate hypoxic and toxic cell damage by increasing cGMP and reducing intracellular Ca2+.
据报道,心房利钠肽浓度升高可减轻体内和离体灌注肾脏中的急性肾衰竭(M. 中本、J.I. 夏皮罗、P.F. 沙利、L. 陈和R.W. 施里尔(1987年)《临床研究杂志》80卷,698 - 705页;S.G. 肖、J. 魏德曼、J. 霍德勒、A. 齐默尔曼和A. 帕特诺斯特罗(1987年)《临床研究杂志》80卷,1232 - 1237页)。由于心房利钠肽已被证明是一种强效血管扩张剂,这种有益作用可能完全归因于血流动力学的改善。为了确定心房利钠肽在细胞水平上是否也具有保护作用,在缺氧(0.5% O₂ ,持续4小时)或活性氧(次氯酸)诱导细胞损伤之前或之后,用心房利钠肽处理大鼠肝细胞培养物。形成泡状、放射性标记的三氯乙酸沉淀肽的降解、乳酸脱氢酶的释放和台盼蓝排斥试验被用作细胞损伤的指标。在这两种情况下,心房利钠肽处理均能明显保护细胞培养物免受损伤。硝普钠部分模拟了心房利钠肽的这种有益作用,硝普钠与心房利钠肽一样,能大幅增加细胞内cGMP含量。颗粒型鸟苷酸环化酶抑制剂6 - 苯胺基 - 5,8 - 喹啉二酮(Ly 83583)可阻断心房利钠肽的保护作用。因此,cGMP介导的机制似乎参与了心房利钠肽的细胞保护作用。使用对Ca²⁺ 敏感的染料喹啉 - 2进行的荧光测量表明,心房利钠肽可防止次氯酸引起的细胞损伤后细胞内Ca²⁺ 的升高。这些结果表明,心房利钠肽可能通过增加cGMP和降低细胞内Ca²⁺ 来减轻缺氧和毒性细胞损伤。